Sebbag Robert
Accès aux médicaments, Sanofi-Aventis.
Bull Acad Natl Med. 2007 Nov;191(8):1601-2.
As a responsible player in the global pharmaceutical industry, Sanofi-Aventis recognizes its special responsibility to provide poor countries with access to drugs and vaccines. This is a key component of the Group's approach to sustainable development. As such, the Access to Medicines department draws on Sanofi-Aventis' expertise in order to address major public health issues, starting with the treatment of malaria, tuberculosis, sleeping sickness, leishmaniasis and epilepsy, as well as access to vaccines. The department has four main activities: research and development of new drugs; improvement of existing treatments; information, communication and education of patients and healthcare professionals; and development of a differential pricing and distribution policy adapted to patients' income, with a "no profit-no loss" equilibrium.
作为全球制药行业中负责任的一员，赛诺菲 - 安万特认识到自己肩负着特殊责任，即让贫困国家能够获得药品和疫苗。这是集团可持续发展战略的关键组成部分。因此，药品可及性部门借助赛诺菲 - 安万特的专业知识，致力于解决重大公共卫生问题，首先是疟疾、结核病、昏睡病、利什曼病和癫痫的治疗，以及疫苗的可及性。该部门有四项主要活动：新药研发；改进现有治疗方法；向患者和医疗保健专业人员提供信息、进行沟通和开展教育；制定适应患者收入的差别定价和分销政策，实现“不盈利不亏损”的平衡。
